<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H860C4140136A4810B66F880876DE1319" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 471 IH: Ensuring Patient Access and Effective Drug Enforcement Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-01-22</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 471</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150122">January 22, 2015</action-date>
			<action-desc><sponsor name-id="M001179">Mr. Marino</sponsor> (for himself, <cosponsor name-id="W000800">Mr. Welch</cosponsor>, <cosponsor name-id="B001243">Mrs. Blackburn</cosponsor>, and <cosponsor name-id="C001080">Ms. Chu of California</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on the <committee-name committee-id="HJU00">Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To improve enforcement efforts related to prescription drug diversion and abuse, and for other
			 purposes.</official-title>
	</form>
	<legis-body id="HE33AEB186A4045DC876AF6227DAAD7C2" style="OLC">
 <section id="HDC34C1E8E36C4D77ACD44381368CDF48" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Ensuring Patient Access and Effective Drug Enforcement Act of 2015</short-title></quote>.</text> </section><section id="HD8D119BD43214C1A9FBBBB6EA5EAD30A"><enum>2.</enum><header>Registration process under Controlled Substances Act</header> <subsection id="HA106978207804790BF96FC7404934210"><enum>(a)</enum><header>Definitions</header> <paragraph id="H73734A28F75F4D449414B95F8E73A260"><enum>(1)</enum><header>Factors as may be relevant to and consistent with the public health and safety</header><text>Section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>) is amended by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="H3C576BEE450D46ED9946E2F6093081BC" style="OLC">
 <subsection id="H2CF3E3813A81414B9D48A1BF8C24C896"><enum>(i)</enum><text display-inline="yes-display-inline">In this section, the phrase <quote>factors as may be relevant to and consistent with the public health and safety</quote> means factors that are relevant to and consistent with the findings contained in section 101.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block> </paragraph><paragraph id="HCFCBE0BB1BE8467D82D16D9993673A45"><enum>(2)</enum><header>Imminent danger to the public health or safety</header><text>Section 304(d) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/824">21 U.S.C. 824(d)</external-xref>) is amended—</text>
 <subparagraph id="HFD62AC54C7F24E26B1DE3C4BD1BA4373"><enum>(A)</enum><text>by striking <quote>(d) The Attorney General</quote> and inserting <quote>(d)(1) The Attorney General</quote>; and</text> </subparagraph><subparagraph id="HBE219BE628C44E2D812CD1A1E170BCBD"><enum>(B)</enum><text>by adding at the end the following:</text>
						<quoted-block display-inline="no-display-inline" id="H04402AC897D047F8B48663BA5193C109" style="OLC">
 <paragraph id="HFE593C9A2FBB4285AF406FB411FAFEEE" indent="up1"><enum>(2)</enum><text display-inline="yes-display-inline">In this subsection, the phrase <term>imminent danger to the public health or safety</term> means that, in the absence of an immediate suspension order, controlled substances—</text> <subparagraph id="H7A534557C32447A8B41BA0F41B7DCCC6"><enum>(A)</enum><text>will continue to be intentionally distributed or dispensed—</text>
 <clause id="H1B9A765A11CF4911B6DCC3036CD8E319"><enum>(i)</enum><text display-inline="yes-display-inline">outside the usual course of professional practice; or</text> </clause><clause id="H78D691F8520740BF9609CBF7257CADDA"><enum>(ii)</enum><text>in a manner that poses a present or foreseeable risk of serious adverse health consequences or death; or</text>
 </clause></subparagraph><subparagraph id="HB3FCE8D4F72B4ECFB908AA7260163F88"><enum>(B)</enum><text>will continue to be intentionally diverted outside of legitimate distribution channels.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block> </subparagraph></paragraph></subsection><subsection id="H4CEBEFA796254C6DB7D5ECC43324DDE2"><enum>(b)</enum><header>Opportunity To submit corrective action plan prior to revocation or suspension</header><text display-inline="yes-display-inline">Subsection (c) of section 304 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/824">21 U.S.C. 824</external-xref>) is amended—</text>
 <paragraph id="HBB553D9F7B8A41709406392A0328C34E"><enum>(1)</enum><text>by striking the last two sentences in such subsection;</text> </paragraph><paragraph id="H25CDD7FDD1B242A8B5BD264041342FE7"><enum>(2)</enum><text>by striking <quote>(c) Before</quote> and inserting <quote>(c)(1) Before</quote>; and</text>
 </paragraph><paragraph id="H4C8E3D55FFD14853A949D867DBC3E25D"><enum>(3)</enum><text>by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="H52BAAF91063E45CEA9D1ED5F0C3ACCBA" style="OLC"> <paragraph id="HD37633F03BF949C48E18CB81A1D7036B" indent="up1"><enum>(2)</enum><text>An order to show cause under paragraph (1) shall—</text>
 <subparagraph id="H28864C7758FE424F96EB1324BD2BD4A6"><enum>(A)</enum><text>contain a statement of the basis for the denial, revocation, or suspension, including specific citations to any laws or regulations alleged to be violated by the applicant or registrant;</text>
 </subparagraph><subparagraph id="H91065D50575047C5810F95931A09CB25"><enum>(B)</enum><text>direct the applicant or registrant to appear before the Attorney General at a time and place stated in the order, but no less than thirty days after the date of receipt of the order; and</text>
 </subparagraph><subparagraph id="HCB903A13418448FBAA838FDAE15861AD"><enum>(C)</enum><text>notify the applicant or registrant of the opportunity to submit a corrective action plan on or before the date of appearance.</text>
 </subparagraph></paragraph><paragraph id="H6E6C0A6A905A413BBD310BC4AABF48F0" indent="up1"><enum>(3)</enum><text>Upon review of any corrective action plan submitted by an applicant or registrant pursuant to paragraph (2), the Attorney General shall determine whether denial, revocation or suspension proceedings should be discontinued, or deferred for the purposes of modification, amendment, or clarification to such plan.</text>
 </paragraph><paragraph id="H74A76613DE154B30A4C0F263C570256E" indent="up1"><enum>(4)</enum><text>Proceedings to deny, revoke, or suspend shall be conducted pursuant to this section in accordance with subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/5">chapter 5</external-xref> of title 5. Such proceedings shall be independent of, and not in lieu of, criminal prosecutions or other proceedings under this title or any other law of the United States.</text>
 </paragraph><paragraph id="H7ECD20D64DEA44EBA8B3D3607F9E67CB" indent="up1"><enum>(5)</enum><text>The requirements of this subsection shall not apply to the issuance of an immediate suspension order under subsection (d).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph></subsection></section><section id="HAC539866E9DF42248E598D0D6FA08EDB"><enum>3.</enum><header>Report to Congress on effects of law enforcement activities on patient access to medications</header>
 <subsection id="H6BFD745EF6AC4BA9ACA7872BA2B8CC9B"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs and the Director of the Centers for Disease Control and Prevention, and in consultation with the Administrator of the Drug Enforcement Administration and the Director of National Drug Control Policy, shall submit a report to the Committee on the Judiciary of the House of Representatives, the Committee on Energy and Commerce of the House of Representatives, the Committee on the Judiciary of the Senate, and the Committee on Health, Education, Labor, and Pensions of the Senate identifying—</text>
 <paragraph id="H030625EBF1C2440EBFD9BB0D8EE7F000"><enum>(1)</enum><text>obstacles to legitimate patient access to controlled substances;</text> </paragraph><paragraph id="H0D1F156C718048CD83B6B28079DB9026"><enum>(2)</enum><text>issues with diversion of controlled substances; and</text>
 </paragraph><paragraph id="HD4113B77D4864005A65364DF0865C0BC"><enum>(3)</enum><text>how collaboration between Federal, State, local, and tribal law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances.</text>
 </paragraph></subsection><subsection id="HE708F6CE910246B98A75FCD25012FCC8"><enum>(b)</enum><header>Consultation</header><text display-inline="yes-display-inline">The report under subsection (a) shall incorporate feedback and recommendations from the following:</text> <paragraph id="H41E2E1E5C16B4B359B506B9EAFC0EA0F"><enum>(1)</enum><text>Patient groups.</text>
 </paragraph><paragraph id="HDA3BE4D28E83410BA32A5D8A74767215"><enum>(2)</enum><text>Pharmacies.</text> </paragraph><paragraph id="H57256C6059D243759CED583938490BEA"><enum>(3)</enum><text>Drug manufacturers.</text>
 </paragraph><paragraph id="H00181310093047C7AF901241D083721C"><enum>(4)</enum><text>Common or contract carriers and warehousemen.</text> </paragraph><paragraph id="H8D43BD0094CB4AFCB1BBA0EE5881ADEA"><enum>(5)</enum><text>Hospitals, physicians, and other health care providers.</text>
 </paragraph><paragraph id="HD76A0E44D4F24A11B583EFA9873B7F99"><enum>(6)</enum><text>State attorneys general.</text> </paragraph><paragraph id="H81BF1BB9552C43819AF54FA34D2873CD"><enum>(7)</enum><text display-inline="yes-display-inline">Federal, State, local, and tribal law enforcement agencies.</text>
 </paragraph><paragraph id="H6D6FB6C3009D43B59F493AF75EBCB4BB"><enum>(8)</enum><text>Health insurance providers and entities that provide pharmacy benefit management services on behalf of a health insurance provider.</text>
 </paragraph><paragraph id="H8A3ABB39CCE5468B854736203901CBEB"><enum>(9)</enum><text>Wholesale drug distributors.</text> </paragraph></subsection></section></legis-body> </bill> 

